Albertsons (ACI) is likely to post a modest upside to identical sales growth estimate of 2% in Q4, RBC Capital Markets said in an earnings preview Thursday.
The consensus estimate was 1.7% for the quarter, the report said. Albertsons will release its Q4 results April 15.
Despite a stable top-line growth, the company faces risks to the fiscal year 2025 adjusted EBITDA positioning, RBC said.
"Pharmacy mix shift will remain a drag and we believe 1H investments are needed to unlock growth potential across retail media and owned brands," the report said.
RBC kept its outperform rating with a $23 price target.
Price: 22.89, Change: +0.46, Percent Change: +2.03
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。